Verve Therapeutics CEO Sekar Kathiresan's 2021 pay jumps 131% to $5.6M
Verve Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 29, 2022
Verve Therapeutics reported fiscal year 2021 executive compensation information on April 29, 2022.
In 2021, three executives at Verve Therapeutics received on average a compensation package of $4.1M, a 137% increase compared to previous year.
Average pay of disclosed executives at Verve Therapeutics
Sekar Kathiresan, Chief Executive Officer, received $5.6M in total, which increased by 131% compared to 2020. 82% of Kathiresan's compensation, or $4.6M, was in option awards. Kathiresan also received $455K in non-equity incentive plan, $519K in salary, as well as $12K in other compensation.
Allison Dorval, Chief Financial Officer, received a compensation package of $3.3M. 91% of the compensation package, or $3M, was in option awards.
Andrew Bellinger, Chief Scientific Officer, earned $3.3M in 2021, a 223% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 29, 2022.